BioDelivery Sciences International announced Monday that it will receive a $10 million milestone payment after its new drug application for its treatment of chronic pain was accepted by the Food and Drug Administration.
Raleigh-based BioDelivery Sciences will receive the payment from Endo Pharmaceuticals, the companyit has partnered with to development the treatment.
The treatment, BEMA Buprenorphine, is being marketed under the brand name Belbuca.
BioDelivery Sciences is also eligible for a milestone payment of up to $50 milion if the new drug application is approved by the FDA. The FDA is expected to rule on the application in October.
BioDelivery Sciences received a $10 million milestone payment from Endo in July after the companies reported positive Phase 3 clinical trial results for Belbuca.